Related Experiment Video
Updated: May 31, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Methemoglobinemia in a newborn: a case report
1Second year resident in pediatric dentistry, Yale University Hospital, New Haven, CT, USA.
Pediatric Dentistry
|June 28, 2011
Summary
A rare case of methemoglobinemia, a serious complication, occurred in a 2-day-old infant after lidocaine injection. This highlights the need for careful risk assessment and management of local anesthetic use in neonates.
Area of Science:
- Anesthesiology
- Pediatric Medicine
- Toxicology
Background:
- Acquired methemoglobinemia is a rare but potentially fatal complication associated with local anesthetics.
- While commonly linked to prilocaine and benzocaine, it can occur with other agents like lidocaine.
- Infants, especially those under 3 months, are particularly vulnerable.
Observation:
- A 2-day-old female infant developed methemoglobinemia and systemic complications following local anesthetic administration.
- Lidocaine, a widely used local anesthetic in dentistry, was implicated in this case.
- The patient experienced severe systemic issues requiring medical intervention.
Findings:
- This case demonstrates that lidocaine, despite its general safety profile, can induce methemoglobinemia in neonates.
- The severity of complications underscores the critical need for prompt diagnosis and management.
- The event highlights potential risks even with commonly used anesthetic agents.
Implications:
- Healthcare providers must be vigilant for methemoglobinemia following lidocaine use, particularly in young children.
- Training in the diagnosis and management of anesthetic-induced methemoglobinemia is crucial for pediatric care.
- A thorough risk-benefit analysis is essential before administering local anesthetics to vulnerable infant populations.
Related Concept Videos
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...